Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 9;74(7):1158-1165.
doi: 10.1093/cid/ciab616.

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

Affiliations

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

Danuta M Skowronski et al. Clin Infect Dis. .

Erratum in

Abstract

Background: Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, Canada, where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included codominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC).

Methods: Analyses included community-dwelling adults ≥ 70 years old with specimen collection between 4 April (epidemiological week 14) and 1 May (week 17) 2021. Adjusted VE was estimated by test-negative design. Cases were reverse-transcription polymerase chain reaction (RT-PCR) test-positive for SARS-CoV-2, and controls were test-negative. Vaccine status was defined by receipt of a single-dose ≥ 21 days before specimen collection, but a range of intervals was assessed. Variant-specific VE was estimated against viruses genetically characterized as Alpha, Gamma or non-VOC lineages.

Results: VE analyses included 16 993 specimens: 1226 (7%) test-positive cases and 15 767 test-negative controls. Of 1131 (92%) genetically characterized viruses, 509 (45%), 314 (28%), and 276 (24%) were Alpha, Gamma, and non-VOC lineages, respectively. At 0-13 days postvaccination, VE was negligible at 14% (95% confidence interval [CI], 0-26) but increased from 43% (95% CI, 30-53) at 14-20 days to 75% (95% CI, 63-83) at 35-41 days postvaccination. VE at ≥ 21 days postvaccination was 65% (95% CI, 58-71) overall: 72% (95% CI, 58-81), 67% (95% CI, 57-75), and 61% (95% CI, 45-72) for non-VOC, Alpha, and Gamma variants, respectively.

Conclusions: A single dose of mRNA vaccine reduced the risk of SARS-CoV-2 by about two-thirds in adults ≥ 70 years old, with protection only minimally reduced against Alpha and Gamma variants.

Keywords: SARS-CoV-2; case-control; test-negative design; vaccine effectiveness; variants of concern.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage vaccinated among SARS-CoV-2 test-positive cases and test-negative controls and case tallies by epidemiological week, participating adults ≥ 70 years of age, British Columbia, Canada, weeks 14–17. Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2.
Figure 2.
Adjusted VE estimates by interval in days since vaccination and restricted by subgroup, adults ≥ 70 years of age, British Columbia, Canada, weeks 14–17. All vaccine effectiveness estimates are adjusted for age group (70–79, 80–89, 90+ years); sex (men, women); epidemiological week (14, 15, 16, or 17); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA). See Supplementary Tables 2–8 for details. VE estimates that are based upon a ≥ 21-day interval between vaccination and specimen collection combine specimens collected 21 or more days since vaccination. Similarly, VE estimates based on a ≥ 42-day interval combine specimens collected 42 or more days since vaccination. Abbreviations: CI, confidence interval; mRNA, messenger RNA; VE, vaccine effectiveness.

References

    1. National Advisory Committee on Immunization (NACI). Recommendations on the use of COVID-19 vaccines. Ottawa: NACI. Available at: https://www.canada.ca/en/public-health/services/immunization/national-ad.... Accessed 27 June 2021.
    1. Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng J Med 2020; 383:2603– 15. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Eng J Med 2020; 384:403– 16. - PMC - PubMed
    1. Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng J Med 2021; 384:10.1056/NEJMc2036242#sa1. - PubMed
    1. Joint Committee on Vaccination and Immunisation (JCVI). Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination. JCVI; 20 Dec 2020. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploa.... Accessed 27 June 2021.

Supplementary concepts